IDH1 and cancer: Moreover, Rac1 and Rictor suppression led to cell viability decrease in IDH1-mutated U251 cells and BTIC TS603, but not in IDH1 wild type U251 cells and BTIC GSC923 (Figure S3D), which indicates that targeting of the mTORC2/Rac1 pathway might be a potential therapeutic approach for cancers with IDH1 mutations.